Advancing Gene Therapy Research for Hemophilia A at MCW
Kristi Castello, Division Administrator III at the Medical College of Wisconsin, reposted from Medical College of Wisconsin on LinkedIn:
Quoting Medical College of Wisconsin‘s post:
”For people with hemophilia A, a simple cut or bump can cause excessive bleeding or bruising. While treatments exist to replace this protein, patients may form antibodies to the current therapies.
For more than two decades, MCW’s David A. Wilcox, PhD has worked with colleagues to develop a new gene therapy that could transform how patients with the disease are treated.
The team has completed preliminary studies of a Phase 1 clinical trial at MCW, ran by MCW’s Dr. Mary Eapen, with a gene therapy that genetically-modifies a patient’s own bone marrow cells to make a blood clotting factor.
Learn more:”
Stay updated with Hemostasis Today.
-
May 11, 2026, 16:52Luke McLaughlin: Raising Awareness on Haemophilia Issues at ENIL Lead On
-
May 11, 2026, 16:49Jeff Sternlicht: Normal LDL Does Not Always Mean Low Risk
-
May 11, 2026, 16:42Archil Jaliashvili: From Managing Blood to Managing Oxygen Metabolism
-
May 11, 2026, 16:42Heghine Khachatryan: Celebrating One Hundred Years of von Willebrand Disease with EHC
-
May 11, 2026, 16:34Jane Hankins: Excited to Have Been a Part of the Faculty of ASH CRTI LA
-
May 11, 2026, 16:28Conan McIlwrath at the Rare Bleeding Disorders Conference Representing The Haemophilia Society as Chair
-
May 11, 2026, 16:24Anna A. Avagyan: Presenting Armenia’s Experience at SIOP Europe 2026
-
May 11, 2026, 16:18Mohamed Elkhider: Raising Awareness on Aortic Dissection
-
May 11, 2026, 16:11David McIntosh: A Pensioner’s Reflections on Blood Donation